243 related articles for article (PubMed ID: 18762709)
1. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs.
Maeda K; Sugiyama Y
Drug Metab Pharmacokinet; 2008; 23(4):223-35. PubMed ID: 18762709
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
3. [Transporters involved in hepatobiliary transport of drugs].
Maeda K
Nihon Yakurigaku Zasshi; 2010 Feb; 135(2):76-9. PubMed ID: 20154415
[No Abstract] [Full Text] [Related]
4. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
5. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2).
Ieiri I
Drug Metab Pharmacokinet; 2012; 27(1):85-105. PubMed ID: 22123128
[TBL] [Abstract][Full Text] [Related]
6. International Transporter Consortium commentary on clinically important transporter polymorphisms.
Giacomini KM; Balimane PV; Cho SK; Eadon M; Edeki T; Hillgren KM; Huang SM; Sugiyama Y; Weitz D; Wen Y; Xia CQ; Yee SW; Zimdahl H; Niemi M;
Clin Pharmacol Ther; 2013 Jul; 94(1):23-6. PubMed ID: 23778707
[TBL] [Abstract][Full Text] [Related]
7. [Role of transporters in hepatic drug disposition].
Gao CY; Chen XY; Zhong DF
Yao Xue Xue Bao; 2012 May; 47(5):565-72. PubMed ID: 22811997
[TBL] [Abstract][Full Text] [Related]
8. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
[TBL] [Abstract][Full Text] [Related]
9. Telmisartan pharmacokinetics in Japanese renal transplant recipients.
Miura M; Satoh S; Inoue K; Saito M; Habuchi T; Suzuki T
Clin Chim Acta; 2009 Jan; 399(1-2):83-7. PubMed ID: 18838068
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition.
Haufroid V
Curr Drug Targets; 2011 May; 12(5):631-46. PubMed ID: 21039333
[TBL] [Abstract][Full Text] [Related]
11. Expression and function of multidrug resistance transporters at the blood-brain barriers.
Scherrmann JM
Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):233-46. PubMed ID: 16922639
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma.
Namisaki T; Schaeffeler E; Fukui H; Yoshiji H; Nakajima Y; Fritz P; Schwab M; Nies AT
Drug Metab Dispos; 2014 Dec; 42(12):2033-40. PubMed ID: 25231932
[TBL] [Abstract][Full Text] [Related]
13. Drug delivery to the brain: considerations of genetic polymorphisms of blood-brain barrier transporters and imaging technologies.
Bai JP
Ther Deliv; 2010 Oct; 1(4):563-70. PubMed ID: 22833967
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications.
Sakurai A; Tamura A; Onishi Y; Ishikawa T
Expert Opin Pharmacother; 2005 Nov; 6(14):2455-73. PubMed ID: 16259577
[TBL] [Abstract][Full Text] [Related]
15. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
[TBL] [Abstract][Full Text] [Related]
16. Impact of organic anion transporting polypeptide, P-glycoprotein, and breast cancer resistance protein transporters on observed tamoxifen and endoxifen concentration and adverse effects.
Keller DN; Medwid SJ; Ross CD; Wigle TJ; Kim RB
Pharmacogenet Genomics; 2023 Jan; 33(1):10-18. PubMed ID: 36373739
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk.
Campa D; Butterbach K; Slager SL; Skibola CF; de Sanjosé S; Benavente Y; Becker N; Foretova L; Maynadie M; Cocco P; Staines A; Kaaks R; Boffetta P; Brennan P; Conde L; Bracci PM; Caporaso NE; Strom SS; Camp NJ; Cerhan JR; ; Canzian F; Nieters A
Int J Cancer; 2012 Aug; 131(4):803-12. PubMed ID: 21918980
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.
Bruhn O; Cascorbi I
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1337-54. PubMed ID: 25162314
[TBL] [Abstract][Full Text] [Related]
19. Transporter-mediated drug-drug interactions.
Müller F; Fromm MF
Pharmacogenomics; 2011 Jul; 12(7):1017-37. PubMed ID: 21787191
[TBL] [Abstract][Full Text] [Related]
20. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo.
Colombo S; Soranzo N; Rotger M; Sprenger R; Bleiber G; Furrer H; Buclin T; Goldstein D; Décosterd L; Telenti A;
Pharmacogenet Genomics; 2005 Sep; 15(9):599-608. PubMed ID: 16041239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
